Opinion|Videos|January 5, 2026
Use of Xanomeline/Trospium in Clinical Practice
Panelists discuss how integrating xanomeline/trospium into clinical practice may expand safe and effective treatment options.
Advertisement
Episodes in this series
Panelists discuss how clinicians are beginning to integrate xanomeline/trospium into practice for patients who have struggled with traditional therapies. They share early observations of improved engagement and cognitive clarity.
Panelists discuss how appropriate patient selection, titration, and adverse effect monitoring are key to maximizing outcomes.
Panelists discuss how broad adoption depends on payer coverage and growing real-world data validating long-term safety and effectiveness.
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
2
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
3
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
4
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
5